Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Insulet Corp (NQ: PODD )

184.78 -0.60 (-0.32%)
Streaming Delayed Price Updated: 10:01 AM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Insulet Corp

< Previous 1 2 3 4 5 6 Next >
Should you consider NASDAQ:PODD for growth investing?
Why INSULET CORP (NASDAQ:PODD) qualifies as a high growth stock. 
Via Chartmill
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
What Stocks Drove The Recent Record Rally? A Breakdown You Can't Miss
The technology sector has done well during the recent stock market rally as seen in indices such as Nasdaq 100 and S&P 500. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why the growth investor may take a look at NASDAQ:PODD.
INSULET CORP (NASDAQ:PODD) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
Expert Ratings for Insulet
Via Benzinga
Why Shares of Insulet Dropped This Week
Positive news regarding diabetes therapy Ozempic worried investors. 
Via The Motley Fool
Barron's Weekend Stock Picks: Chevron, Apple, Disney And Insulet's Stock Increase
Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read. 
Via Benzinga
Insulet Surges After Eye-Popping Earnings Growth Wallops Expectations
Insulet makes an insulin pump called Omnipod. U.S. sales are on the rise. 
Via Investor's Business Daily
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
14 Analysts Have This to Say About Insulet
Via Benzinga
Why Insulet Stock Is Sinking Today
Comments from Insulet's CEO at a major healthcare conference rattled investors. 
Via The Motley Fool
Omnipod Insulin Pump Working Well For Insulet, Lifts Annual Forecast
Insulet Corporation (NASDAQ: PODD) reported Q3 sales of $432.7 million, up 27.0%, or 25.1% in constant currency, beating the  
Via Benzinga
Weight-Loss Drugs Spooked Medical Device Stocks. Did Investors Overreact?
Makers of devices to treat obesity-related conditions have struggled recently. Analysts say there's more to the story. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Insulet Stock Traded Lower
Insulet Corporation (NASDAQ: PODD) shares traded lower Thursday. 
Via Benzinga
Palantir And PwC Team Up To Accelerate Data-Driven Operations, OpenAI Rival Secures Billions In Big Tech Backing, Six US States Brace For Healthcare Strike: Today's Top Stories
Benzinga 
Via Benzinga
Tubeless Insulin Pump Technology Provider Insulet's CFO Resigns; Reaffirms Q3, FY23 Outlook
Medical device company Insulet Corp (NASDAQ: PODD) disclosed that Wayde McMillan has decided to resign as Executive Vice President,  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 2, 2023
Via Benzinga
FedEx To Rally Around 19%? Here Are 10 Other Analyst Forecasts For Monday
JP Morgan raised the price target for The Progressive Corporation (NYSE: PGR) from $146 to $149. JP Morgan analyst Jimmy Bhullar maintained an Overweight rating. Progressive shares fell 0.8% to close... 
Via Benzinga
Is It Time to Buy the S&P 500's 4 Worst-Performing Stocks This Year?
The broad-market index is up but these stocks are down. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
September's Shakeout: S&P 500, Nasdaq 100 See Just 13% Of Stocks Above 50-Day Average
The September market downturn is spreading like wildfire across various sectors, with only a handful of stocks managing to maintain the positive trend seen in recent months. 
Via Benzinga
Topics Stocks
Exposures US Equities
Navigating The S&P 500 Landscape: Here Are The Stocks Analysts Believe Have The Highest Potential And Biggest Downside
In the middle of the AI revolution and the Federal Reserve's steadfast stance on interest rates, the stock market has seen unexpected twists and turns. Despite hopes of the U.S. 
Via Benzinga
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
The 7 Most Undervalued Stocks in the Market Right Now: September 2023
Buying these undervalued stocks right now can pay off tremendously once these fundamentally solid businesses ultimately recover. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 386 stocks made new 52-week lows. 
Via Benzinga
Apple Taps Seasoned Executive To Head 'Secret' Team Developing Glucose Monitoring Device - Stocks To Watch
Apple Inc (NASDAQ: AAPL) has appointed Tim Millet, a seasoned executive with a background in iPhone and Mac chip technology, to oversee its secretive team dedicated to developing a noninvasive blood... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 169 companies set new 52-week lows. 
Via Benzinga
Why Toro Are Trading Lower By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers American Rebel Holdings, Inc. (NASDAQ: AREB) shares jumped 100% to $1.7909 after the company's subsidiary Champion Safe has been bombarded with calls from safe dealers and customers looking for... 
Via Benzinga
Is It Time to Buy the S&P 500's 3 Worst-Performing August Stocks?
The S&P 500 had a rare decline last month. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Dexcom Says It Won't Be The Biggest Loser In The Weight-Loss Battle — And Shares Soar
Dexcom says the popularity of GLP-1 drugs won't hurt its continuous glucose monitors. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.